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The burden of non-communicable disease in South Africa (SA) is 
escalating. Undiagnosed and uncontrolled diabetes mellitus (DM) 
are common in patients requiring surgery. Access to resources and 
expertise to safely control blood glucose levels in the perioperative 
period are variable in the SA public healthcare system. The 
combination of an increasing burden of disease and inadequate 
perioperative diabetes management is likely to increase surgical 
complication rates, mortality and cost of care. 
This article focuses on perioperative diabetes management of 
type 1 and type 2 DM patients who are undergoing surgery in a non-
critical care setting. Obstetric, paediatric and critical care patients are 
excluded from this discussion. 
Burden of disease
Type 2 DM is the most common type of diabetes, representing 
>90% of the DM disease burden in SA. The International Diabetes 
Federation reports that there are currently ~1.8 million adults in 
SA known to have DM, while a further 1.5 million adults remain 
undiagnosed.[1] The SA National Health and Nutrition Examination 
Survey (SANHANES) 2012 showed a national prevalence of abnormal 
glucose regulation of 18.6%, varying according to ethnicity and 
degree of urbanisation. According to SANHANES, 45% of people 
with diabetes were previously undiagnosed.[2] 
Over the past decade, DM has become one of the major underlying 
causes of mortality globally; in SA it now ranks second only to 
tuberculosis.[3]
The SA Surgical Outcomes Study (SASOS) reports a 10.2% 
prevalence of diabetes in our surgical population (5.8% non-insulin 
dependent, and 4.4% insulin dependent).[4]
Diabetes mellitus in the perioperative 
context
The perioperative period is associated with worsening glycaemic 
control, probably due to the stress response of surgery.[5] Starvation, 
tissue trauma and pain lead to increased levels of pro-inflammatory 
mediators and circulating stress hormones. These substances 
alter insulin secretion and sensitivity, producing a state of relative 
insulin resistance, protein catabolism and lipolysis with liberation 
of free fatty acids. This state can extend for multiple days into the 
postoperative period, driving adverse patient outcomes.[6] These 
include increased mortality, increased length of hospital stay, as well 
as increased infective (surgical site infections, urinary tract infections 
and pneumonia) and non-infective complications (cardiac events, 
acute kidney injury and stroke).[7] 
Protocol-driven quality improvement projects result in improved 
perioperative glycaemic control, but strict control strategies increase 
hypoglycaemic events.[8,9] As hypoglycaemia has been linked to 
mortality, it is essential to avoid the condition by targeting a 
perioperative blood glucose level in the range of 6.0 - 10.0 mmol/L.[10] 
A capillary blood glucose (CBG) measurement up to 12.0 mmol/L 
may be tolerated for brief periods if it is regularly monitored and 
expected to decrease.[11,12] 
Hyperglycaemia in the perioperative period may be due to 
physiological stress and should not be diagnosed as DM without input 
from the local diabetes healthcare provider. Stress hyperglycaemia 
without DM is a poorly understood entity, the management of which 
remains unclear.[5] 
Perioperative management
Consider perioperative management of DM in three phases: 
preoperative, intraoperative, and postoperative. 
Preoperative 
In the preoperative phase the patient with DM must be identified 
and assessed to define a perioperative management plan. Screen 
for undiagnosed DM according to the Society for Endocrinology, 
Diabetes and Metabolism of SA (SEMDSA) guidelines.[13] Evaluate the 
diabetic patient’s capacity to manage the disease, chronic glycaemic 
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control and invasiveness of the planned surgery. Where available, 
a glycated haemoglobin (HbA1c) should be used to determine 
adequacy of glycaemic control in those diagnosed with diabetes. An 
elevated HbA1c correlates with poor patient outcomes after surgery 
and an HbA1c >8.5% (69 mmol/mol) warrants postponement of 
elective surgery.[11,12] More stringent cut-off values are recommended 
by some, but may currently be unattainable in many parts of SA.[14] 
The patient’s comorbidities and glycaemic control should always 
be optimised before elective surgery. In an emergency, there is little 
time for optimisation, as surgery must proceed promptly. Often 
though, patients present for surgery that is time sensitive. In this 
‘grey zone’ between elective and emergency, the timing of surgery 
should be determined by a multidisciplinary team with a patient-
centred discussion about how best to balance risk and benefit.[15] 
The decision to proceed with surgery in the face of uncontrolled DM 
must acknowledge the increased risk to the patient and define ways 
to manage this risk. 
Resources and access to expertise vary among healthcare centres. 
It is therefore important to choose an appropriate perioperative 
glycaemic management plan. Although many options are available, 
four are commonly used and recommended (Table 1): 
• modification of usual treatment (Tables 2 and 3) 
• basal-bolus subcutaneous (SC) insulin (Fig. 1) 
• Alberti’s glucose-insulin-potassium (GIK) intravenous infusion 
(Box 1) 
• variable rate intravenous insulin infusion (VRIII) (Fig. 2). 
Monotherapy with SC short- or rapid-acting insulin according to 
a sliding scale is not recommended for in-hospital management of 
DM, as it increases the risk of hypoglycaemia and provides inferior 
glycaemic control.[16,17]
In all cases, limiting of the starvation period has to be planned, as 
well as where the patient will be managed postoperatively (day case, 
surgical ward or high-care facility). For short starvation periods (one 
missed meal), modification of the usual medication will often 
suffice (Tables 2 and 3). Missing more than one perioperative meal is 
considered a prolonged starvation period. If the CBG is >12 mmol/L, it 
will necessitate either basal SC insulin or an intravenous insulin infusion. 
Intraoperative 
The intraoperative phase starts at the time of arrival in theatre and 
continues until transfer to the postoperative ward. The patient with 
DM must have a documented CBG prior to commencement of 
anaesthesia. While under anaesthesia, the CBG should be monitored 
at least 2-hourly, more frequently if abnormal and in patients 
receiving insulin.[18] If the intraoperative CBG levels were abnormal, 
the CBG measurement should be repeated in the post-anaesthetic 
recovery area.
When possible, administer SC short- or rapid-acting insulin to 
avoid unnecessary intravenous insulin for short surgical procedures. 
Limit SC short- or rapid-acting insulin to two intraoperative doses. 
In type 2 DM, a first dose of 0.1 U/kg (up to a maximum of 6 U) is 
appropriate; alternatively, use the correction dosing scale in Fig. 1 
as a starting point. To prevent insulin stacking intraoperatively, do 
not administer a top-up dose of SC insulin within 2 hours of the 
first dose. Intravenous insulin is preferred when SC insulin does 
not control hyperglycaemia. This is common in surgery of longer 
duration, prolonged starvation and emergency cases.[11] 
Table 1. Indications, advantages and disadvantages of four perioperative diabetes management strategies
Management Indications Advantages Disadvantages
Modification of usual 
therapy
HbA1c <8.5%
Short starvation period
(<1 meal missed)
Lowest risk for hypoglycaemia 
Decreased burden on ward staff 
Suitable for patient self-management 
Often not possible, as patients have 
poor baseline control or there is 
prolonged starvation 
Basal-bolus SC insulin 
with correction doses
Those already on basal-bolus insulin 
Type 1 diabetes
Patients with poor baseline control 
Newly diagnosed DM requiring 
perioperative insulin therapy 
Short surgical duration 
Where IV insulin therapy is not 
feasible
Improved glycaemic control
Flexible dosing
Decreased risk of hypoglycaemia 
Intensive
Regular monitoring required
Not to be used if the patient is not 
eating meals 
Unpredictable absorption when there 
is impaired tissue perfusion
Alberti’s glucose-
insulin-potassium 
infusion 
Poor control on SC insulin 
(CBG >12.0 mmol/L)
Prolonged starvation period
(>1 meal missed) 
Long surgical duration
Periods of inadequate tissue perfusion
High-care or ICU setting 
VRIII is not an option
Improved glycaemic control
Flexible 
Labour intensive 
Need trained staff
Risk of hypo-Na+/K+
Risk of hypoglycaemia
VRII Poor control with SC insulin 
(CBG >12.0 mmol/L)
Prolonged starvation period
(>1 meal missed) 
Long surgical duration 
Periods of inadequate tissue
perfusion
High-care or ICU setting
Improved glycaemic control
Flexible
Requires specialised equipment 
Labour intensive
Need trained staff
Risk of hypo-Na+/K+
Risk of hypoglycaemia
SC = subcutaneous; DM = diabetes mellitus; IV = intravenous; CBG = capillary blood glucose; ICU = intensive care unit; VRIII = variable rate intravenous insulin infusion.
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Postoperative 
After surgery, intravenous insulin therapy must not be discontinued 
without overlapping and restarting the patient’s basal SC insulin.
Check the CBG before discharge from the post-anaesthetic recovery 
area. Ensure that the patient is sent to the appropriate level of care for 
continuation of their glycaemic control strategy. Early reinstatement 
of normal enteral feeding and usual antidiabetic medication is the 
goal. The agents and regimen used for glycaemic control will largely 
depend on the feeding status of the patient (Table 4). 
Safe insulin therapy 
Insulin is an extremely potent agent. Drug errors can cause significant 
harm to the patient. Staff education and involvement of the local 
pharmacy are needed to ensure constant safe prescribing, dispensing 
and dosing practices.[19] 
There is a real risk of diabetic ketoacidosis (DKA) with transition 
to and from intravenous insulin therapy. Delays in commencing the 
intravenous insulin infusion, and discontinuation of the infusion 
prior to administration of basal insulin, cause acute insulin deficiency 
in insulin-dependent patients.[20] This risk can be mitigated by 
continuation of basal SC insulin while using intravenous insulin, or 
by administration of intermediate- or long-acting insulin 30 minutes 
before discontinuing the intravenous insulin (GIK or VRIII).[12] 
Non-insulin antidiabetic agents
Non-insulin antidiabetic agents should not be started in the 
immediate perioperative period. These medications have multiple 
contraindications and are not rapidly titratable. However, diabetic 
patients who are well controlled could be considered for continuation 
of their non-insulin agents during the perioperative period. Guidance 
Table 2. Summary of non-insulin antidiabetic agents with recommendations for perioperative management[21,22] 
Management Class of drug (examples) Considerations Recommendations
Insulin sensitisers Biguanides 
Metformin
Does not cause hypoglycaemia
Risk of lactic acidosis 
Continue while eating
Omit on day of surgery
Omit if risk of renal impairment 
(IV contrast, other nephrotoxic agents, 
haemodynamic instability)
Omit if >1 meal missed
Thiazolidinediones 
Pioglitazone (roziglitazone)
Does not cause hypoglycaemia
Concern of hepatotoxicity 
Contraindicated in 
haemodynamic instability
Omit on day of surgery 
Restart when tolerating meals 
Secretagogues Sulphonylureas
Glibenclamide 
Gliclazide
Glimepiride
Risk of hypoglycaemia Omit while fasting
Restart when tolerating meals 
Meglitinides 
Repaglinide
Nateglinide
Risk of hypoglycaemia Omit while fasting
Restart when tolerating meals
Incretin family GLP-1 analogues 
Exenatide
Liraglutide
Delayed gastric emptying 
concern for aspiration risk
Injectable only
Limited information
May improve perioperative glycaemic 
control 
DPP-4 inhibitors (gliptins)
Saxagliptin
Vildagliptin
Limited information
May improve perioperative glycaemic 
control
Increased glucosuria SGLT-2 inhibitors (gliflozins)
Empagliflozin
Dapagliflozin
Association with DKA Avoid in the perioperative period
Impairs absorption Alpha-glucosidase inhibitors
Acarbose
Causes severe flatulence and 
bloating
Avoid in the perioperative period
GLP-1 = glucagon-like peptide 1; DPP-4 = dipeptidyl peptidase-4; SGLT-2 = sodium-glucose co-transporter 2; DKA = diabetic ketoacidosis; IV = intravenous.
Table 3. Perioperative modification of insulin therapy*† 
Insulin regimen‡ Day before surgery Day of surgery
Once daily (evening dosing) intermediate- or long-acting insulin Reduce dose by 20% Restart insulin with evening meal
Once daily (morning dosing) intermediate- or long-acting insulin Usual dose Reduce dose by 20%
Twice daily dosing 
Premixed insulin, or intermediate- or long-acting insulin 
Usual dose Reduce morning dose to 50% 
Normal evening dose with dinner
Basal-bolus regimen Usual bolus doses 
Reduce night-time basal 
dose by 20%
If basal dose in the morning, reduce by 20%
Omit bolus doses while fasting 
*Adapted from the Joint British Diabetes Society for Inpatient Care guidelines, with permission.[11]
†Appropriate where no more than one meal missed in the perioperative period. 
‡Check capillary blood glucose regularly while fasting. The majority of international guidelines advise 1- or 2-hourly measurements. Protocols with a 4-hourly measurement interval carry a 10% 
hypoglycaemia risk.[18] 
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on the management of these agents during 
the perioperative period is given in Table 2. 
Modification of oral therapy as the primary 
perioperative glycaemic control strategy is 
only appropriate in uncomplicated surgical 
patients who miss one meal during the 
perioperative period. Critically ill patients, 
those with poor glycaemic control and those 
who miss multiple meals, should be managed 
with an appropriate insulin regimen.[21,22] 
Hypoglycaemia
The perioperative period represents an 
increased risk for undiagnosed hypoglycae-
mia while patients are fasting and under the 
influence of sedative agents. Whenever insu-
lin is prescribed in hospital, hypoglycaemia 
treatment must be prescribed on the same 
chart. Perioperatively, a CBG <6.0 mmol/L 
should be interpreted as imminent hypogly-
caemia. A CBG <4.0 mmol/L is associated 
with harm and must be treated. Interruption 
of insulin therapy is discouraged, but dose 
reduction may be necessary. Assess the 
patient with a low CBG for signs and symp-
toms of hypoglycaemia. Consider their feed-
ing status (eating or fasting) and their risk 
of hypoglycaemia unawareness. Fig. 3 pro-
vides a suggested hypoglycaemia manage-
ment algorithm. While under the influence 
of anaesthesia, treat all patients with a low 
CBG with intravenous dextrose. If the CBG 
is ˂6.0 mmol/L, administer 10 g intravenous 
dextrose; if the CBG is ˂4.0 mmol/L, give 
20 g intravenous dextrose. Thereafter, the 
CBG should be measured every 15 minutes 
and treatment repeated until the blood glu -
cose is corrected.[11] 
Special circumstances 
SC insulin infusion (SCII) (or insulin 
pump therapy) is increasingly used in the 
management of type 1 DM. Patients using 
an insulin pump should,as far as possible, 
maintain control of their own peri operative 
glycaemic management. When assessing 
these patients, consider the invasiveness, 
duration and site of the surgery, as well 
as the anticipated postoperative course. 
Question how many meals the patient will 
skip. Will the anaesthetist have access to 
the SCII intraoperatively? Will the device 
location infringe on the surgical site? Ideally, 
a preoperative basal test is done to establish 
glycaemic response to the fasting state. If 
this was not done, ask the patient to decrease 
the SCII to 70 - 80% of the basal rate while 
fasting. Ensure that the anaesthetic provider 
understands how to adjust, discontinue and 
remove the SCII if necessary. If continued 
intraoperatively, one or two small (2 - 4 U) 
SC correctional doses of insulin may be 
administered if the CBG rises ≥10.0 - 
12.0 mmol/L. If this fails to correct the 
CBG, start a VRIII. If the CBG decreases to 
˂4.0 - 6.0 mmol/L, treat the hypoglycaemia 
with intravenous dextrose. If hypoglycaemia 
persists, disconnect the SCII and switch to a 
VRIII. SCII is not appropriate for emergency 
surgery or where more than one meal is 
missed in the perioperative period.[23,24]
For patients with DM, day-case surgery 
must be considered.[14] It reduces the risk of 
iatrogenic complications and empowers the 
patient to manage their own perioperative 
glycaemic control. When assessing diabetic 
patients for day-case surgery, three aspects 
must be considered: 
• Is the patient physically, mentally and 
socioeconomically capable to self-manage 
their DM and do they have easy access to 
emergency healthcare should they need it? 
• Is their DM adequately controlled, with a 
recent HbA1c <8.5%? 
• Is the nature of the surgery suitable for a 
day case?
A multidisciplinary context-
sensitive approach 
No single scenario describes every patient 
with DM who has to undergo surgery. At 
each facility (or group of facilities) a repre-
sentative multidisciplinary team must evalu-
ate the unique patient-resource environment 
and develop an evidence-based clinical prac-
tice guideline that fits their context. Smaller 
facilities should obtain input from their 
regional specialist centre. 
It is essential to empower patients to self-
manage their diabetes, especially in a setting 
where access to resources or healthcare 
personnel is limited. When appropriate, 
patients should be given guidance to 
manage their own insulin and non-insulin 
antidiabetic therapy in the ward.[21] 
The dietician, or equivalent team member, 
must engage the kitchen service to ensure 
Three components 
• Basal – once daily intermediate- or long-acting insulin
•  Bolus – dosing at meal times with short- or rapid-acting insulin 
•  Correction – additional dosing at meal times with short- or rapid-acting insulin 
to achieve or maintain the desired individualised glycaemic target
For patients already on insulin, start with the patient’s usual TDD
For insulin-naive patients, start with a TDD of 0.2 - 0.3 U/kg/day
â
Give 50% of the TDD as basal insulin
Give 50% of the TDD as bolus doses (divide into 3 equal doses and give 
before each meal)
â
Give correction doses (added to the already prescribed insulin doses) 
according to the following dosing scale:
Insulin correction dose, U
CBG, mmol/L
Level 1 (insulin 
sensitive, incl. 
fasting) 
Level 2
(usual patient)
Level 3 (insulin 
resistant, 
TDD >80 U) 
10.1 - 12.0
12.1 - 14.0
14.1 - 16.0
16.1 - 20.0
>20.0
2
3
4
5
6
4
6
8
10
12
6
9
12
15
18
To prevent insulin stacking, allow at least 4 hours between SC doses of insulin 
Two-hourly dosing is acceptable intraoperatively
Reduce the basal doses to 80% of the usual dose on the night before and the 
morning of surgery 
Omit prandial dosing while fasting 
Provide hypoglycaemia management instructions wherever insulin is 
prescribed
Fig. 1. Basal-bolus insulin regimen.[16,25,26] (TDD = total daily dose; CBG = capillary blood glucose; 
SC = subcutaneous.)
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Box 1.  Alberti glucose-insulin-potassium infusion[21,27]
The GIK infusion is an alternative IV insulin regimen when a VRIII is not feasible.  It provides substrate, IV insulin and electrolytes via a single 
infusion.
The original GIK regimen was published by Alberti and Thomas in 1979. It provides a safe and effective method of giving substrate, IV insulin 
in the same infusion. Alterations of the original regimen remain in use today.[28,29,30] 
The original GIK regimen uses a bag containing 500 mL 10% dextrose and adds:
• 10 U short-acting insulin
• 10 mL 10% KCl.
The infusion runs at a fixed rate of 100 mL/h, providing 2 U insulin per hour.  
CBG is measured 1 - 2-hourly. To increase or decrease the insulin infusion rate by 1 U/h the insulin content of the bag is changed up or down 
by 5 U. A new bag must be mixed each time it is decided to adjust the insulin infusion rate. 
Problems with the GIK infusion are: 
• labour intensive and wasteful when multiple bag changes are needed
• maintenance at 100 mL/h exceeds current standards for care of surgical patients
• 500 mL 10% dextrose bags are not available at all locations
• 10% dextrose water is not an acceptable maintenance fluid
• risk of DKA in type 1 DM if GIK infusion is stopped.
If deemed appropriate for the location, the local multidisciplinary team must adapt the GIK regimen to suite their context and address the 
concerns mentioned. Involve specialist input. 
GIK = glucose-insulin-potassium; IV = intravenous; VRIII = variable rate intravenous insulin infusion; CBG = capillary blood glucose; DKA = diabetic ketoacidosis; DM = diabetes mellitus.
Use a dedicated IV access site and infusion set with an antireflux valve for glucose management
Add 50 U of regular short-acting insulin to 50 mL 0.9% NaCl (1 mL = 1 U)
Administer with a syringe driver connected to a port close to the dedicated IV cannula 
Run dextrose-containing maintenance solution at 25 mL/kg/day (20 - 30 mL/kg/h range)
Monitor serum Na+ and K+ daily
Measure CBG hourly while the patient is under the influence of anaesthesia; 2-hourly if normoglycaemic, awake, attended, 
and not confused
Insulin rates, mL/h
CBG, mmol/L
Level 1 (insulin sensitive, 
incl. fasting) Level 2 (usual patient)
Level 3 (insulin resistant, 
TDD >80 U)
<4.0 Reduce VRIII to 0.2 - 0.5 mL/h (stop VRIII if SC basal insulin continued)
Administer 20 g dextrose IV
Repeat CBG in 15 min
4.1 - 6.0 Reduce VRIII to 0.2 - 0.5 mL/h (stop VRIII if SC basal insulin continued)
Consider administration of 10 g dextrose IV to prevent CBG decreasing to ˂4.0 mmol/L
Repeat CBG in 15 min
6.1 - 8.0 0.5 1 2
8.1 - 12.0 1 2 4
12.1 - 16.0 2 4 6
16.1 - 20.0 3 5 7
20.1 - 24.0 4 6 8
>24.1 6 8 10
Seek specialist advice
Target CBG range 6.0 - 12.0 mmol/L. CBG up to 12.0 mmol/L is acceptable for a short period 
Only increase VRIII if CBG remains high after 3 hours and is decreasing by ˂3 mmol/L/h 
There is a risk of DKA when discontinuing a VRIII, as it creates a state of acute insulin withdrawal
Continue SC basal insulin while using a VRIII or administer SC basal insulin 30 min before discontinuing a VRIII 
Fig. 2. Variable rate intravenous insulin infusion regimen.[21,22]  (CBG = capillary blood glucose; IV = intravenous; TDD = total daily dose; VRIII = variable 
rate intravenous insulin infusion; SC = subcutaneous; DKA = diabetic ketoacidosis.) 
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that the diabetic diet provides a constant 
caloric intake from meal to meal and day to 
day. This will reduce prandial fluctuations 
in blood glucose and reduce the need for 
correction doses of insulin. The surgical 
team should understand the meal plan to 
ensure that minimal time elapses from the 
start of preoperative fasting until the first 
postoperative meal. 
The local protocol should consider how care 
will be escalated for selected patients. Every DM 
patient cannot be referred to a diabeto logist. 
Also define how feedback on perioperative DM 
management will be used to bring the patient 
back into the primary healthcare system after 
the perioperative period.
Conclusion
DM is an ever-growing public health prob-
lem affecting patient outcomes after surgery. 
This article addresses the SA scope of the 
problem and provides a structure for manag-
ing the patient with DM presenting for sur-
gery. A local multidisciplinary team should 
guide practice at each facility. The recom-
mended reading section provides essential 
information for individual perioperative 
providers and teams caring for surgical 
patients with DM. Where a patient scenario 
falls outside the scope of this discussion, the 
provider must consult the local multidisci-
plinary team or referral specialist centre for 
guidance. 
Key points 
• DM is a modifiable risk factor of adverse 
surgical outcomes. Undiagnosed DM or 
an HbA1c >8.5% (69 mmol/mol) is an 
indication to postpone elective surgery.
• Monotherapy using SC short- or rapid-
acting insulin according to a sliding scale 
is not recommended.
• In all patients with DM, attempt to mini-
mise the starvation period to only one 
missed meal.
• A CBG range of 6.0 - 10.0 mmol/L is the 
recommended target in the perioperative 
period. A CBG up to 12 mmol/L may be 
acceptable. 
• Safe insulin prescribing practice requires 
prescription of hypoglycaemia treatment 
on every insulin prescription chart. 
• In-hospital interruption of insulin therapy 
is a common cause of DKA in patients 
with type 1 DM.
• A multidisciplinary team should drive 
context-sensitive perioperative manage-
ment of DM. 
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Table 4. Blood glucose management according to feeding status
Feeding status Management options
Eating normally Modification of usual therapy or basal-bolus SC insulin with 
correction doses 
Fasting VRIII, modified Alberti’s GIK, or basal insulin only* 
Tube enteral feeding VRIII, modified Alberti’s GIK, or basal insulin only* 
Total parenteral feeding VRIII, modified Alberti’s GIK, or basal insulin only* 
SC = subcutaneous; VRIII = variable rate intravenous insulin infusion; GIK = glucose-insulin-potassium infusion.
*It is best to avoid short- or rapid-acting insulin, as there is an increased risk of hypoglycaemia. However, small correction 
doses with frequent monitoring may be required if glucose readings are >12 mmol/L.
Provide the diagnostic criteria and management of hypoglycaemia with every 
in-patient diabetes prescription
A low CBG must be interpreted in the context of the patient’s feeding status and 
symptomatology
Decide whether the patient is at risk of hypoglycaemia unawareness. These 
include the frail, patients on beta-blockers, with long-standing DM, and those on 
medications with sedative effects. All such patients, including those under the 
influence of anaesthesia, should automatically be treated as symptomatic
CBG, 
mmol/L
Without symptoms and 
signs of hypoglycaemia
With symptoms or signs of 
hypoglycaemia
Normal diet Fasting Normal diet Fasting
<4.0 Provide a 
snack and 
repeat the 
CBG in 15 - 
30 min
Give 10 g 
dextrose IV 
and repeat 
the CBG in 15 
- 30 min
Give 20 g 
dextrose IV 
and repeat 
CBG in 15 min 
Seek urgent 
help if no 
response to 
treatment
Give 20 g 
dextrose IV and 
repeat CBG in 
15 min
Seek urgent 
help if no 
response to 
treatment
4.0 - 6.0 Increase 
monitoring 
frequency 
Repeat CBG 
within 30 min 
If persistent, 
give 10 g 
dextrose IV 
and increase 
monitoring 
frequency
Provide a 
snack and 
repeat CBG in 
15 - 30 min 
Give 10 g 
dextrose IV and 
repeat CBG in 
15 min
Seek urgent 
help if no 
response to 
treatment
Fig. 3. Management of perioperative hypoglycaemia. (CBG = capillary blood glucose; DM = diabetes 
mellitus; IV = intravenous.)
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